These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 21788131)

  • 41. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
    Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
    Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.
    Dobre EG; Nichita L; Popp C; Zurac S; Neagu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma.
    Ruiz-Garcia E; Matus-Santos JA; Guadarrama-Orozco JA; Alvarez-Avitia MA; Aguilar-Ponce JL; Fernandez-Figueroa E; Maldonado-Mendoza J; Lopez-Camarillo C; Marchat LA; Lino-Silva S; Cuellar-Hubbe M; de la Garza-Salazar J; Meneses-García A; Astudillo-de la Vega H; Martinez-Said H
    J Glob Oncol; 2018 Sep; 4():1-5. PubMed ID: 30241212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Kodali N; Bhattaru A; Blanchard I; Sharma Y; Lipner SR
    Melanoma Res; 2024 Oct; 34(5):419-428. PubMed ID: 38564430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur.
    Kang X; Zeng Y; Liang J; Li J; Ren D; Chai L; Sun Z; Yu S; Wu X; Han W; Wang W
    Medicine (Baltimore); 2018 Jan; 97(1):e9509. PubMed ID: 29505523
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.
    Thomas NE; Edmiston SN; Kanetsky PA; Busam KJ; Kricker A; Armstrong BK; Cust AE; Anton-Culver H; Gruber SB; Luo L; Orlow I; Reiner AS; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Parrish EA; Hao H; Gibbs DC; Frank JS; Ollila DW; Begg CB; Berwick M; Conway K;
    J Invest Dermatol; 2017 Dec; 137(12):2588-2598. PubMed ID: 28842324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histologic and Phenotypic Factors and MC1R Status Associated with BRAF(V600E), BRAF(V600K), and NRAS Mutations in a Community-Based Sample of 414 Cutaneous Melanomas.
    Hacker E; Olsen CM; Kvaskoff M; Pandeya N; Yeo A; Green AC; Williamson RM; Triscott J; Wood D; Mortimore R; Hayward NK; Whiteman DC
    J Invest Dermatol; 2016 Apr; 136(4):829-837. PubMed ID: 26807515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.
    Cheung CHY; Cheng CK; Lau KM; Ip RKL; Chan NCN; Tam THC; Wong RSM; Raghupathy R; Chan NPH; Ng MHL
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e315-e325. PubMed ID: 29807803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
    Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.